Virtual Tumor Board: EGFR-mutant NSCLC

from Lung Cancer Considered Hosted by IASLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Sara Pilotto and Dr. Jonathan Riess for a virtual tumor board discussion on the management of metastatic EGFR exon 19 NSCLC . Using a complex case featuring discordant biomarker results and brain metastases, the panel explores first-line treatment strategies including osimertinib monotherapy, FLAURA2 (osimertinib plus chemotherapy), and MARIPOSA (amivantamab plus lazertinib), as well as sequencing at progression, re-biopsy, CNS considerations, and the evolving role of local consolidation and clinical trials.

Episode details come from the podcast's RSS feed.

Embed this episode

Attribution link and audio player

Ready to play

Virtual Tumor Board: EGFR-mutant NSCLC

0:00 47:44

No transcript yet.

Requests help us decide what to transcribe next.

Share this episode

Similar podcasts

Lung Cancer Update for Nurses Dr Neil Love Featuring one-on-one interviews conducted by Dr Neil Love with national lung cancer clinical investigators and oncology nurses, this series provides practicing clinicians including nurses and nurse practitioners with valuable information and current clinical management strategies that can be applied to optimize patient care.

Frequently asked questions

How long is this episode of Lung Cancer Considered?

This episode is 47 minutes long.

When was this Lung Cancer Considered episode published?

This episode was published on March 3, 2026.

Can I download this Lung Cancer Considered episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.